Nelarabine (Atriance) is a deoxyguanosine analog prodrug. It exerts anti-leukemic effects by inhibiting DNA synthesis and is developed by Novartis.
Indications of Nelarabine (Atriance)
Main Indications
T-cell acute lymphoblastic leukemia (T-ALL).
T-cell lymphoblastic lymphoma (T-LBL).
Key Instructions
Target Population: Adult patients and pediatric patients aged ≥ 1 year.
No response to at least two previous chemotherapy regimens.
Or relapse after treatment.
Contraindications: No absolute contraindications, but caution should be exercised regarding severe neurotoxicity.
Specifications and Properties of Nelarabine (Atriance)
Specifications
Strength: 250mg/50mL (5mg/mL) in single-dose glass vials.
Appearance: Colorless and clear solution, with a pH of 5.0-7.0.
Active Ingredient: Each milliliter contains 5mg of nelarabine (in the form of nelarabine hydrochloride monohydrate).
Excipients: Sodium chloride (4.5mg/mL), no natural latex components.
Dosage Form Characteristics
Stability: Can be stably stored for 8 hours (≤ 30°C) in PVC infusion bags or glass containers.
Usage Restrictions: Must be administered by intravenous infusion. The infusion time is 2 hours per dose for adults and 1 hour per dose for children.
Storage Methods of Nelarabine (Atriance)
Temperature Control
Store at 20°C to 25°C (68°F to 77°F).
Short-term exposure to 15°C to 30°C (59°F to 86°F) is allowed.
Packaging Protection
Original glass vials provide effective light protection; the product must be used immediately after opening.
Freezing or storage at high temperatures (e.g., in cars, direct sunlight) is prohibited.
Safe Storage
Keep out of the reach of children.
Discard any unused portion.
Special Note: If the solution changes color or develops particles, it should be discarded immediately.
